Corrigendum: Interferon-α2b Treatment for COVID-19

Affiliations

¹ Department of Respiratory and Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
² Prevention of Organ Failure (PROOF) Centre of Excellence & Centre for Heart Lung Innovation, St Paul's Hospital, University of British Columbia, Vancouver, BC, Canada.
³ Division of Respiratory Medicine, Department of Medicine, University of British Columbia, Vancouver, BC, Canada.
⁴ Systems Vaccinology, Center for Precision Health, Telethon Kids Institute, Nedlands, WA, Australia.
⁵ Toronto General Hospital Research Institute, University Health Network & Department of Immunology, University of Toronto, Toronto, ON, Canada.

Published Erratum

Qiong Zhou et al. Front Immunol. 2020.

. 2020 Oct 27:11:615275.

doi: 10.3389/fimmu.2020.615275. eCollection 2020.

¹ Department of Respiratory and Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
² Prevention of Organ Failure (PROOF) Centre of Excellence & Centre for Heart Lung Innovation, St Paul's Hospital, University of British Columbia, Vancouver, BC, Canada.
³ Division of Respiratory Medicine, Department of Medicine, University of British Columbia, Vancouver, BC, Canada.
⁴ Systems Vaccinology, Center for Precision Health, Telethon Kids Institute, Nedlands, WA, Australia.
⁵ Toronto General Hospital Research Institute, University Health Network & Department of Immunology, University of Toronto, Toronto, ON, Canada.

Abstract

[This corrects the article DOI: 10.3389/fimmu.2020.01061.].

Keywords: ARDS; COVID-19; IL-6; inflammation; interferon; viral shedding.

Interferon-α2b Treatment for COVID-19.
Zhou Q, Chen V, Shannon CP, Wei XS, Xiang X, Wang X, Wang ZH, Tebbutt SJ, Kollmann TR, Fish EN. Zhou Q, et al. Front Immunol. 2020 May 15;11:1061. doi: 10.3389/fimmu.2020.01061. eCollection 2020. Front Immunol. 2020. PMID: 32574262 Free PMC article. Clinical Trial.